Table 1 Patient demographics and disease characteristics
|  | Sarilumab SC 200 mg q2w (n = 184) | Adalimumab SC 40 mg q2w (n = 185) |
|---|---|---|
Demographics | ||
 Age, years, mean ± SD | 50.9 ± 12.6 | 53.6 ± 11.9 |
 Female sex, n (%) | 157 (85.3) | 150 (81.1) |
 Race, white, n (%) | 171 (92.9) | 164 (88.6) |
 Weight, kg, mean ± SD | 72.3 ± 16.5 | 71.8 ± 17.8 |
 BMI, kg/m2, mean ± SD | 27.1 ± 5.6 | 27.3 ± 6.5 |
Geographic region, n (%)a | ||
 1 | 61 (33.2) | 62 (33.5) |
 2 | 36 (19.6) | 35 (18.9) |
 3 | 87 (47.3) | 88 (47.6) |
Disease and treatment history | ||
 Duration of RA, years, mean ± SD | 8.1 ± 8.1 | 6.6 ± 7.8 |
 Rheumatoid factor-positive, n (%)b | 119 (66.9) | 116 (64.8) |
 Anti-CCP autoantibody-positive, n (%)c | 134 (75.3) | 138 (76.7) |
Number of prior csDMARDs, n (%) | ||
 0 | 0 | 0 |
 1 | 83 (45.1) | 88 (47.6) |
 2 | 57 (31.0) | 58 (31.4) |
  ≥ 3 | 44 (23.9) | 39 (21.1) |
Prior csDMARDs other than MTX, n (%)d | Â | Â |
 Sulfasalazine | 59 (32.1) | 44 (23.8) |
 Leflunomide | 42 (22.8) | 45 (24.3) |
 Hydroxychloroquine | 41 (22.3) | 43 (23.2) |
Prior csDMARDs in combination with MTX, n (%) | 35 (19.0) | 44 (23.8) |
Reason for stopping MTX, n (%) | ||
 Inadequate responder | 97 (52.7) | 103 (55.7) |
 Intolerant | 87 (47.3) | 81 (43.8) |
 Inappropriate for continued treatment | 0 | 1 (0.5) |
Concomitant oral corticosteroids, n (%) | 98 (53.3) | 104 (56.2) |
Disease activity, mean ± SD | ||
 DAS28-ESRe | 6.8 ± 0.8 | 6.8 ± 0.8 |
 DAS28-CRPe | 6.0 ± 0.9 | 6.0 ± 0.9 |
 Swollen joint count (66 assessed)e | 18.6 ± 10.7 | 17.5 ± 10.3 |
 Tender joint count (68 assessed)e | 28.0 ± 13.2 | 26.7 ± 13.6 |
 CDAIe | 43.6 ± 12.1 | 42.4 ± 12.0 |
 ESR, mm/he | 46.5 ± 21.8 | 47.5 ± 23.2 |
 CRP, mg/Le | 17.4 ± 21.3 | 24.1 ± 31.0 |